Pharmaceuticals

SHANGHAI YIZHONG

SHANGHAI YIZHONG released FY2026 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 79.16 M, actual EPS CNY 0.09

SHANGHAI YIZHONG to Release FY2026 Q1 Earnings on April 28 After-Market BJT

SHANGHAI YIZHONG FY2025 Earnings Release on April 28 During-Market BJT

SHANGHAI YIZHONG released FY2025 Q4 earnings on February 2, 2026 During-Market (BJT), actual revenue CNY 73.95 M, actual EPS CNY 0.0613

SHANGHAI YIZHONG released FY2025 earnings on February 2 During-Market (BJT), actual revenue CNY 317.08 M, actual EPS CNY 0.31

SHANGHAI YIZHONG released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 243.13 M, actual EPS CNY 0.2466

SHANGHAI YIZHONG released FY2025 Q3 earnings on October 29 During-Market (BJT), actual revenue CNY 82.82 M, actual EPS CNY 0.0681

SHANGHAI YIZHONG FY2025 Q3 Earnings Release Scheduled for October 30 During-Market BJT

Shanghai Yizhong Reports Q2 2025 Revenue and Net Profit Growth

SHANGHAI YIZHONG released FY2025 Q2 earnings on August 7 After-Market (BJT), actual revenue CNY 89.28 M, actual EPS CNY 0.1084

SHANGHAI YIZHONG released FY2025 Semi-Annual earnings on August 7 After-Market (BJT), actual revenue CNY 160.31 M, actual EPS CNY 0.18

SHANGHAI YIZHONG to Release FY2025 Semi-Annual Earnings on August 8, 2025 (BJT)

Shanghai Kaibao Reduces Shares in Shanghai Yizhong

Shanghai Yizhong Shareholders' Block Trade Fully Subscribed

Shanghai Xianyu Plans to Reduce Holdings in Shanghai YiZhong by Up to 2%

Shanghai Yizhong Reports a Significant Drop in Net Profit in 2024

Shanghai YiZhong Q1 2025 Revenue Up 3.39% YoY

上海仪众在 4 月 22 日盘后 (北京时间) 发布了 2025 财年第 1 季度业绩，实际营收 7103 万 CNY，实际 EPS 0.07 CNY

Shanghai Yizhong to Release FY2025 Q1 Earnings on April 23 After-Market BJT

Shanghai Yizhong FY2024 Annual Earnings Release on April 23, 2025 (BJT)

300878

688221

600513

688443

688091

The A-share innovative drug sector surged in the afternoon, with WECOME rising over 15%, Frontier Biotechnologies and SHANGHAI YIZHONG rising over 10%, and JLPC, Hongbo Pharmaceutical, Genrix Bio, and Chengda Pharmaceutical following suit

Wallstreetcn

WECOME

Froniter Biotechnologies

JLPC

Genrix Bio

Huayuan Securities released a research report indicating that the pharmaceutical industry will continue to improve marginally in 2025, with operational performance expected to further improve in 2026. It is recommended to focus on structurally high-growth sub-sectors and individual stocks, particularly the integration of the PD1/VEGF/IL-2 triple antibody mechanism. It is recommended to pay attention to SHANGHAI YIZHONG, as its developed triple antibody YXC-001 has high feasibility in treatment strategies and is expected to show significant advantages in efficacy and immune activation

Zhitong

HuaYuan Securities: The potential of PD1/VEGF/IL-2 is promising, insisting on innovative drugs as the main line for the whole year

603127

06127

002262

000813

603590

300363

Innovative drug concept stocks fluctuated and rose sharply, DEZHAN HEALTHCARE hit the limit up, Porton, JOINN, NHWA, Konruns, and SHANGHAI YIZHONG followed suit

JOINN

NHWA

DEZHAN HEALTHCARE

Konruns

Porton

Innovative drug concept stocks fluctuate and rise, DEZHAN HEALTHCARE hits the limit up

According to the Zhitong Finance APP, SHANGHAI YIZHONG announced that the company plans to repurchase shares for between 30 million and 35 million yuan, with the repurchase price not exceeding 106.08 yuan per share, and all will be used to maintain the company's value and shareholder rights

SHANGHAI YIZHONG plans to repurchase shares for 30 million to 35 million yuan

SHANGHAI YIZHONG announced that Chairman Zhou Jinsong proposed to repurchase part of the company's shares through centralized bidding. The total amount of funds for the repurchase is not less than 30 million yuan and not more than 35 million yuan, with the source of funds being self-owned funds or self-raised funds. The repurchase price shall not exceed 150% of the average trading price of the company's shares over the 30 trading days prior to the board of directors' approval of the repurchase resolution. The repurchase period is within 3 months from the date of the shareholders' meeting's approval of this repurchase plan

SHANGHAI YIZHONG: The chairman proposed to repurchase shares worth 30 million to 35 million yuan

688428

09969

In the A-share market, some biopharmaceutical stocks weakened, with Nanmo Biology down 9%, SHANGHAI YIZHONG down over 7%, INNOCARE down over 5%, Sunshine Novo Nordisk and Guangsheng Tang down over 4%, Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Biology, and Qianyan Biology down over 3%

InnoCare Pharma

INNOCARE

Some A-share biopharmaceutical stocks weakened, SHANGHAI YIZHONG fell over 7%, INNOCARE fell over 5%

002173

688265

300436

Pharmaceutical stocks showed divergence during the session, with Cosunter plunging nearly 10%, while InnoCare Pharma, SMOC, SHANGHAI YIZHONG, and Innovative Medical all saw significant declines

Innovative Medical

SMOC

Cosunter

Pharmaceutical stocks show divergence during trading, with Cosunter experiencing a significant drop

688336

688098

300049

300199

688621

In the morning session, the innovative drug concept became active again, with Shen Lian Biomedical hitting a two-day limit-up, Furui Co., Ltd. reaching a 20% limit-up, and HYBIO, Sun-Novo, SHANGHAI YIZHONG, and Sunshine Guojian Pharmaceutical rising over 5%. According to news, the "China Innovative Drug and Medical Device Multi-Payment White Paper" shows that the estimated scale of China's innovative drug and medical device market in 2024 is about 162 billion yuan. The white paper predicts that by 2035, the market size of innovative drugs and medical devices in China will exceed 1 trillion yuan

Sunshine Guojian Pharmaceutical

Shen Lian Biomedical

Furui Co.,Ltd.

HYBIO

Sun-Novo

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

SHANGHAI YIZHONG released its semi-annual performance for 2025, with revenue of 160 million yuan, a year-on-year increase of 31.48%; net profit attributable to the parent company of 38 million yuan, a year-on-year increase of 10.13%; net profit excluding non-recurring items of 37.06 million yuan, a year-on-year increase of 11.74%; basic earnings per share of 0.18 yuan. The growth in performance is mainly attributed to the inclusion of the core product paclitaxel micelles in the national medical insurance catalog, with sales increasing by 487%

SHANGHAI YIZHONG released its semi-annual performance, with a net profit attributable to shareholders of 38 million yuan, a year-on-year increase of 10.13%

According to the Zhitong Finance APP, SHANGHAI YIZHONG disclosed the pricing situation for the transfer of shares through shareholder inquiry. After inquiring with institutional investors, the preliminary transfer price determined for this inquiry transfer is RMB 53.98 per share. The shares intended for transfer in this inquiry have been fully subscribed, with the preliminary determination of the transferees being 8 institutional investors, and the total number of shares to be transferred is 2,067,037 shares

SHANGHAI YIZHONG: The preliminary inquiry transfer price is set at 53.98 yuan/share

SHANGHAI YIZHONG(688091.SH)